MB

Dr. Mohamad H. Badawi

WVUPC Pediatric Surgery Office
Charleston, WV
Specialties:Pediatric Hematology Oncology | Pediatrics
Clinical Trials:Currently Recruiting for 16 Trials
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Mohamad H. Badawi's experience treating your condition:
About Dr. Mohamad H. Badawi

Mohamad Badawi is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in Charleston, West Virginia. His top areas of expertise are Myeloproliferative Neoplasms (MPN), Malignant Teratoma of the Mediastinum, Adult Soft Tissue Sarcoma, and Leukemia. He is licensed to treat patients in West Virginia.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 19 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Mohamad H. Badawi it is best to call his office and ask if your insurance is accepted.

Call to see if your plan is accepted.
Locations
830 Pennsylvania Ave, Charleston, WV 25302
Background & Education
Specialties
Pediatric Hematology Oncology
Pediatrics
Licenses
Pediatrics in WV
Hospital Affiliations
CAMC General Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Procedure, Drug, Biological, Radiation
Study Drugs: CyclophosphamideDoxorubicin HydrochlorideEtoposide PhosphateFilgrastimNivolumabPegfilgrastimPrednisolonePrednisoneRituximabRituximab+Hyaluronidase HumanVincristine Sulfate
Study Phase: Phase 3
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia AsparaginaseBlinatumomabCyclophosphamideCytarabineDexamethasoneDoxorubicin HydrochlorideLeucovorin CalciumMercaptopurineMethotrexatePegaspargasePrednisolonePrednisoneThioguanineVincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Enrollment Status: Recruiting
Publish Date: December 02, 2022
Intervention Type: Drug, Biological
Study Drugs: AxitinibNivolumab
Study Phase: Phase 2
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Radiation, Drug, Procedure
Study Drugs: CarboplatinCyclophosphamideDoxorubicinEtoposideIfosfamideIrinotecanTopotecanVincristine
Study Phase: Phase 2
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: BleomycinBleomycin SulfateCarboplatinCisplatinEtoposideEtoposide Phosphate
Study Phase: Phase 3
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 3
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Drug, Other, Procedure
Study Drugs: CarboplatinCisplatinDoxorubicinEtoposideFluorouracilGemcitabineIrinotecanOxaliplatinSorafenibVincristine Sulfate
Study Phase: Phase 2/Phase 3
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Other, Procedure, Drug
Study Drug: Tyrosine Kinase Inhibitor
Study Phase: Phase 2
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: November 03, 2022
Intervention Type: Drug, Biological, Radiation, Other
Study Drugs: CalaspargaseCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinInotuzumabLeucovorin6-MercaptopurineMethotrexatePegaspargasePrednisoloneThioguanineVincristine
Study Phase: Phase 3
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: October 21, 2022
Intervention Type: Other
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Recruiting
Publish Date: October 21, 2022
Intervention Type: Drug, Other
Study Drugs: CarboplatinCyclophosphamideDoxorubicin HydrochlorideEtoposide
Study Phase: Phase 3
Renal Tumors Classification, Biology, and Banking Study
Enrollment Status: Recruiting
Publish Date: September 07, 2022
Intervention Type: Other
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
Enrollment Status: Recruiting
Publish Date: August 04, 2022
Intervention Type: Drug, Biological, Radiation
Study Drug: Cyclophosphamide
Study Phase: Phase 3
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Enrollment Status: Recruiting
Publish Date: May 04, 2022
Intervention Type: Procedure, Drug, Behavioral
Study Drugs: AsparaginaseErwinia AsparaginaseCytarabineDaunorubicinDexrazoxaneEtoposideGemtuzumabGilteritinibLiposomal DaunorubicinLiposomal CytarabineMethotrexateMitoxantroneHydrocortisone
Study Phase: Phase 3
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Enrollment Status: Recruiting
Publish Date: April 13, 2022
Intervention Type: Drug
Study Drugs: MebendazoleVincristineCarboplatinTemozolomideBevacizumabIrinotecan
Study Phase: Phase 1/Phase 2
Pain Control in Pediatric Oncology: Utility of EMLA Cream vs Lidocaine Injection in Lumbar Punctures
Enrollment Status: Recruiting
Publish Date: January 27, 2020
Intervention Type: Drug
Study Drugs: Lidocaine/PrilocaineLidocaine
Study Phase: Phase 4
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Suspended
Publish Date: November 28, 2022
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: CyclophosphamideDactinomycinIrinotecan hydrochlorideTemsirolimusVincristine sulfateVinorelbine
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active, not recruiting
Publish Date: October 20, 2022
Intervention Type: Drug, Other
Study Drugs: AsparaginaseErwinia AsparaginaseCytarabineDaunorubicinEtoposideMitoxantroneThioguanine
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active, not recruiting
Publish Date: October 19, 2022
Intervention Type: Other, Procedure
View 3 Less Clinical Trials -
3 Total Publications
Predictors of Poor Adherence to Follow-up Care in Survivors of Childhood Cancer.
Journal: Oncology (Williston Park, N.Y.)
Published: June 20, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
CK
Dr. Chandra M. Kumar
Allergy and Immunology | Pediatrics
Highly rated in
1
conditions
Allergy and Immunology
Pediatrics

WVU Medicine

Wv Asthma And Allergy Centers Inc

208 Maccorkle Ave Se, 
Charleston, WV 
 0.7 mi

Chandra Kumar is an Allergy and Immunologist and a Pediatrics expert in Charleston, West Virginia. Kumar has been practicing medicine for over 58 years and is highly rated in 1 condition, according to our data. His top areas of expertise are Sinusitis, Allergic Rhinitis, Pediatric Myocarditis, Cataract Removal, and Endoscopy. He is licensed to treat patients in West Virginia. Kumar is currently accepting new patients.

KU
Dr. Krishna K. Umapathi
Pediatrics | Pediatric Cardiology
Highly rated in
2
conditions
Pediatrics
Pediatric Cardiology

Charleston, WV 
 0.1 mi

Krishna Umapathi is a Pediatrics specialist and a Pediatric Cardiologist in Charleston, West Virginia. Umapathi is highly rated in 2 conditions, according to our data. His top areas of expertise are Childhood Pancreatitis, Congenital Heart Disease (CHD), Obesity in Children, and Infectious Myocarditis. He is licensed to treat patients in West Virginia, Ohio, and Illinois.

HH
Dr. Holly A. Hill-Reinert
Pediatrics
Highly rated in
1
conditions
Pediatrics

Community Health Association

701 Madison Ave, 
Madison, WV 
 23.4 mi

Holly Hill-Reinert is a Pediatrics expert in Madison, West Virginia. Hill-Reinert has been practicing medicine for over 12 years and is highly rated in 1 condition, according to our data. Her top areas of expertise are Pediatric Myocarditis, Childhood Pancreatitis, Urinary Tract Infection in Children, and Osteomyelitis in Children. She is licensed to treat patients in West Virginia. Hill-Reinert is currently accepting new patients.